Condition: Non Small Cell Lung Cancer · Sponsor: ETOP IBCSG Partners Foundation
ADOPT-lung is an international, multicentre, open-label randomised phase III trial. Protocol treatment consists of 3-4 cycles of neoadjuvant durvalumab in combination with platinum-based doublet chemotherapy, followed by surgery. Patients with R0 and R1 only resection will be randomised to receive either adjuvant durvalumab for 12 cycles (experimental arm) or observation (control arm). The primary objective of the study is to determine whether additional adjuvant immunotherapy with durvalumab after neoadjuvant chemo-immunotherapy has an effect on disease-free survival (DFS) in patients who do not achieve complete pathological response (pCR) as per local assessment according to the IASLC recommendations.
This description comes directly from the study's public registry record.
Heidi Roschitzki, PhD · +41 31 511 94 00 · heidi.roschitzki@etop.ibcsg.org
Susanne Roux · +41 31 511 94 00 · ADOPT-lung@etop.ibcsg.org
Always discuss trial participation with your own doctor first.
| Chris O'Brien Lifehouse | Camperdown, New South Wales, Australia | Not Yet Recruiting |
| Nepean Hospital | Penrith, New South Wales, Australia | Recruiting |
| Royal North Shore Hospital | St Leonards, New South Wales, Australia | Recruiting |
| Princess Alexandra Hospital | Woolloongabba, Queensland, Australia | Not Yet Recruiting |
| Flinders Medical Centre | Bedford Park, South Australia, Australia | Not Yet Recruiting |
| Royal Hobart Hospital | Hobart, Tasmania, Australia | Not Yet Recruiting |
| Eastern Health | Box Hill, Victoria, Australia | Recruiting |
| Alfred Hospital | Melbourne, Victoria, Australia | Recruiting |
| Peter MacCallum Cancer Centre | Parkville, Victoria, Australia | Recruiting |
| Sir Charles Gairdner Hospital | Nedlands, Western Australia, Australia | Not Yet Recruiting |
| Wien AKH | Vienna, Austria | Recruiting |
| Institut Jules Bordet - HUB | Anderlecht, Belgium | Recruiting |
+ 30 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06284317